Neurophet Supplies 'Neurophet AQUA' to Raffles Medical in Singapore

Providing Neurophet AQUA capable of analyzing brain atrophy and white matter degeneration… Securing

Neurophet receives FDA 510(k) Clearance for Neurophet AQUA

Neurophet Signs MOU with ALZ-NET to Facilitate Imaging Monitoring Infrastructure for Alzheimer's Disease Therapies

Aims to improve quality of care for patients with Alzheimer's disease… Exploring adoption of Neurophet's key

Neurophet and The Florey Strengthen Research Collaboration on 'Neurophet AQUA' to Advance Alzheimer's Disease Diagnosis

Aiming to evaluate the utility of blood-based and other biomarkers for Alzheimer's disease diagnosis and

Neurophet Participates in BIO USA 2025: To showcase Brain Imaging Analysis Solutions Including 'Neurophet AQUA AD'

Highlight brain imaging analysis solutions, including 'Neurophet AQUA AD', which monitors side effects from

Neurophet Secures FDA 510(k) Clearance for "Neurophet AQUA AD Plus," Marking Its Third U.S. Regulatory Milestone

Following AQUA and SCALE PET, the latest FDA clearance reinforces Neurophet's leadership in AI-based